The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis.

摘要: Background Budesonide is a potent corticosteroid commonly prescribed for management of inflammation in chronic rhinosinusitis (CRS). The standard prescribing budesonide via impregnated nasal saline irrigation (INSI), although recently the mucosal atomization device (MAD) has emerged as theoretically superior method distributing medication into sinuses. MAD atomizes small droplets and this thought to enhance absorption improve bioavailability. However, no studies have shown whether enhanced improved bioavailability causes adrenal suppression. objective study determine affects hypothalamic-pituitary-adrenal (HPA) axis. Methods Twenty CRS patients were recruited from tertiary rhinology clinic randomized take (1 mg) or INSI twice day 60 days. adrenocorticotropic hormone (ACTH) stimulation test 22-item Sinonasal Outcomes Test (SNOT-22) questionnaire administered on days 1, 30, 60 study. Plasma cortisol levels simultaneously quantified using high-performance liquid chromatography–tandem mass spectrometry technique. Results There was indication suppression either group (n = 20) based ACTH results nor there significant plasma detected group. Quality life, indicated by SNOT-22, did not differ between groups at 60 days (p 0.404; 95% confidence interval [CI], −37.2 15.9), but SNOT-22 scores show statistically improvement compared baseline 0.02). Conclusion The likely safe effective delivering sinuses short term.